K-RAS is known as the most frequently mutated oncogene. However, the development of
conventional K-RAS inhibitors has been extremely challenging, with a mutation-specific …

Drug resistance continues to be a major problem associated with cancer treatment. One of
the primary causes of anticancer drug resistance is the frequently mutated RAS gene. In …

The affinity-directed protein missile (AdPROM) system utilizes specific polypeptide binders
of intracellular proteins of interest (POIs) conjugated to an E3 ubiquitin ligase moiety to …

Mutations to RAS proteins (H-, N-, and K-RAS) are among the most common oncogenic
drivers, and tumors harboring these lesions are some of the most difficult to treat. Although …

The function and significance of RAS proteins in cancer have been widely studied for
decades. In 2013, the National Cancer Institute established the RAS Initiative to explore …

Despite nearly four decades of effort, broad inhibition of oncogenic RAS using small-
molecule approaches has proven to be a major challenge. Here we describe the …

The Ras proteins are aberrantly activated in a wide range of human cancers, often
endowing tumors with aggressive properties and resistance to therapy. Decades of effort to …

K-Ras proteins are major drivers of human cancers, playing a direct causal role in about one
million cancer cases/year. In cancers driven by mutant K-Ras, the protein is locked in the …

HRAS, NRAS, and KRAS4A/KRAS4B comprise the RAS family of small GTPases that
regulate signaling pathways controlling cell proliferation, differentiation, and survival. RAS …

Cyclic peptides have great potential as therapeutic agents and research tools. However,
their applications against intracellular targets have been limited, because cyclic peptides are …